This study focuses on patients with norepinephrine-refractory vasoplegic shock, a severe condition where blood vessels become abnormally dilated, leading to dangerously low blood pressure that does not respond adequately to standard treatment with norepinephrine. The study will test a medication called Reverpleg (also known as argipressin or arginine vasopressin), which is given through an intravenous infusion.
The purpose of this research is to determine if early treatment with Reverpleg can improve outcomes compared to placebo in patients with this type of shock. During the study, patients will receive either Reverpleg or placebo through an intravenous line for up to 7 days. They will also receive standard medical care, including a solution of sodium chloride for fluid replacement.
The study will monitor various aspects of patient recovery, including survival, kidney function, and how long patients need medication to maintain their blood pressure. Patients will be followed for up to 90 days to assess their recovery and any potential side effects of the treatment.



France